^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Bladder Cancer

    Related cancers:
    1d
    Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study (clinicaltrials.gov)
    P3, N=486, Recruiting, NRG Oncology | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> May 2026
    Enrollment open • Trial initiation date
    |
    cisplatin • gemcitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical
    1d
    Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer. (PubMed, Clin Cancer Res)
    Among cisplatin-ineligible patients with MIBC, nivolumab alone was well tolerated. Ipilimumab/nivolumab caused toxicity that delayed cystectomy. Cases of progression before cystectomy indicated insufficient efficacy of pure neoadjuvant immunotherapy for unselected patients. Despite low response rates, some patients experienced sustained clinical CRs without cystectomy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    NCOR1 (Nuclear Receptor Corepressor 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    1d
    BL13: Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer (clinicaltrials.gov)
    P2, N=82, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab)
    2d
    ERBB2 mutations promote recurrence and metastasis in non-muscle-invasive bladder cancer via HIF-1 phosphorylation: Insights from whole exome sequencing. (PubMed, J Pharm Anal)
    In vivo studies using mouse models further supported these findings, showing that ERBB2 mutations promote tumor growth, metastasis, and macrophage infiltration. Collectively, these results suggest that ERBB2 mutations drive NMIBC progression by stabilizing HIF-1 through phosphorylation, thereby facilitating tumor development and immune modulation, and underscore the potential of ERBB2 as a therapeutic target for preventing NMIBC recurrence and metastasis.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    HER-2 mutation
    2d
    Polyarginine Peptide R11-Actin Interaction Induces a Domino Effect on Cytoskeleton Remodeling to Suppress Bladder Cancer Metastasis. (PubMed, Research (Wash D C))
    Remarkably, nanoscale multivalent assemblies of R11 amplify these effects through enhanced multivalent binding to actin. This study unveils a new strategy for cytoskeleton-targeted intervention through peptide-based precision materials, highlighting R11 assemblies as a promising therapeutic platform for the treatment of metastatic BCa and potentially other cytoskeleton-dependent malignancies.
    Journal
    |
    VIM (Vimentin)
    2d
    A novel tumor-progressing fibroblast signature derived from single-cell RNA sequencing enables prognostic stratification and reveals RNF11 as a functional regulator in bladder cancer. (PubMed, Front Mol Biosci)
    Functional characterization showed that RNF11 regulates proliferation and migration of bladder cancer. These findings highlight the prognostic value of CAF signatures and provide a framework for precision medicine approaches in bladder cancer management.
    Journal
    |
    FOXA1 (Forkhead Box A1) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1)
    3d
    Lactylation Enhances YTHDF3 Stability to Promote Cisplatin Resistance via m6A-Dependent KDM6B Decay in Bladder Cancer. (PubMed, Cancer Lett)
    Functional assays further demonstrate that YTHDF3 knockdown enhances cisplatin sensitivity in bladder cancer cells and xenograft tumors, whereas enforced expression of KDM6B or CDKN1A phenocopies the cisplatin-sensitizing effect of YTHDF3 knockdown. Collectively, our findings define a lactate-AARS2-YTHDF3-KDM6B-CDKN1A axis that integrates metabolic reprogramming, m6A-dependent epitranscriptomic regulation, and epigenetic chromatin remodeling to drive cisplatin resistance in bladder cancer.
    Journal
    |
    KDM6B (Lysine Demethylase 6B) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • YTHDF3 (YTH N6-Methyladenosine RNA Binding Protein F3)
    |
    cisplatin
    3d
    ReplaceCysto: Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance (clinicaltrials.gov)
    P2, N=240, Recruiting, White River Junction Veterans Affairs Medical Center | Phase classification: P=N/A --> P2
    Phase classification
    |
    Bladder EpiCheck® • Xpert® Bladder Cancer Monitor
    3d
    Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology. (clinicaltrials.gov)
    P=N/A, N=266, Recruiting, Qilu Hospital of Shandong University
    New trial
    3d
    Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology (clinicaltrials.gov)
    P=N/A, N=254, Recruiting, Qilu Hospital of Shandong University
    New trial
    3d
    Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology. (clinicaltrials.gov)
    P=N/A, N=224, Recruiting, Qilu Hospital of Shandong University
    New trial
    4d
    Ad-VT Oncolytic Adenovirus Suppresses Bladder Cancer via cAMP-Dependent AMPK-Raptor Activation and G2/M Arrest. (PubMed, Tumour Virus Res)
    This was confirmed by pathway inhibitors (Dorsomorphin, ESI-09) and siRNA knockdown, which reversed cell cycle arrest and reduced cytotoxicity...Crucially, AMPK inhibition attenuated Ad-VT's antitumor effects. These results demonstrate that Ad-VT exerts potent, tumor-selective activity against bladder cancer by inducing cAMP-dependent AMPK-Raptor-mTOR signaling and G2/M arrest, supporting its therapeutic potential.
    Journal
    |
    CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • CCNB1 (Cyclin B1)
    |
    dorsomorphin (Compound C)